Bronchopulmonary dysplasia: Clinical practices in five portuguese neonatal intensive care units

Revista Portuguesa de Pneumologia

Volumn 16, Issue 2, 2010, Pages 273-286

  Guimaraes H ^a   Rocha, G ^a   Vasconcellos, G ^a   Proenca E ^b   Carreira, M L ^c   Sossai, M R ^d   Morais, B ^d   Martins, I ^e   Rodrigues, T ^f   Severo, M ^f  

^a HOSPITAL DE SÃO JOÃO   (Portugal)

^b Matern Julio Dinis   (Portugal)

^c HOSPITAL DE SANTO ANTÓNIO   (Portugal)

^d HOSPITAL FERNANDO FONSECA   (Portugal)

^e HOSPITAL PEDRO HISPANO   (Portugal)

^f University of Porto   (Portugal)

Author keywords

Better practices; Bronchopulmonary dysplasia; Mechanical ventilation; Neonatal intensive care; Oxygen therapy; Patent ductus arteriosus; Prenatal corticosteroids; Preterm infants; Sepsis

Indexed keywords

CORTICOSTEROID;

ARTICLE; BRAIN HEMORRHAGE; CLINICAL PRACTICE; CONGENITAL MALFORMATION; CONTROLLED STUDY; FEMALE; GESTATIONAL AGE; HEALTH CARE QUALITY; HEALTH CENTER; HOSPITAL ADMISSION; HUMAN; INFANT; INTENSIVE CARE UNIT; LUNG DYSPLASIA; LUNG INJURY; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; NEUROMUSCULAR DISEASE; OXYGEN THERAPY; PATENT DUCTUS ARTERIOSUS; PRACTICE GUIDELINE; PREVALENCE; SEPSIS; VERY LOW BIRTH WEIGHT; CLINICAL TRIAL; COMPARATIVE STUDY; MULTICENTER STUDY; NEWBORN; NEWBORN INTENSIVE CARE; PORTUGAL;

BRONCHOPULMONARY DYSPLASIA; FEMALE; HUMANS; INFANT, NEWBORN; INFANT, VERY LOW BIRTH WEIGHT; INTENSIVE CARE UNITS, NEONATAL; MALE; PORTUGAL;

EID: 77955940082     PISSN: 08732159     EISSN: None     Source Type: Journal    
DOI: 10.1016/s2173-5115(10)70035-x     Document Type: Article

References (59)

1. Northway WH Jr, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med 1967; 276(7):357-368.
2. Bancalari E, Abdenour GE, Feller R, Gannon J. Bronchopulmonary dysplasia: clinical presentation. J Pediatr 1979; 95(5 Pt 2):819-823.
3. Shennan AT, Dunn MS, Ohlsson A, Lennox K, Hoskins EM. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics 1988; 82(4):527-532.
4. Walsh MC, Yao Q, Gettner P, Hale E, Collins M, Hensman A, Everette R, Peters N, Miller N, Muran G, Auten K, Newman N, Rowan G, Grisby C, Arnell K, Miller L, Ball B, McDavid G; National Institute of Child Health and Human Development Neonatal Research Network. Impact of a physiologic definition on bronchopulmonary dysplasia rates. Pediatrics 2004; 114(5):1305-1311.
5. Ehrenkranz RA, Walsh MC, Vohr BR, Jobe AH, Wright LL, Fanaroff AA, Wrage LA, Poole K; National Institutes of Child Health and Human Development Neonatal Research Network Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics 2005; 116(6):1353-1360.
6. Sosenko IRS, Bancalari E. New developments in the presentation, pathogenesis, epidemiology and prevention of bronchopulmonary dysplasia. In: The Newborn Lung Eduardo Bancalari. Consulting Ed: Richard A Polin. Saunders Elsevier 2008: 187-207.
7. Crossing the Quality Chasm: A new health system for the 21st century. Washington DC: National Academy 2001.
8. Payne NR, LaCorte M, Karna P, Chen S, Finkelstein M, Goldsmith JP, Carpenter JH. Breathsavers Group, Vermont Oxford Network Neonatal Intensive Care Quality Improvement Collaborative. Reduction of bronchopulmonary dysplasia after participation in the Breathsavers Group of the Vermont Oxford Network Neonatal Intensive Care Quality Improvement Collaborative. Pediatrics 2006; 118(Suppl 2):S73-S77.
9. Payne NR, LaCorte M, Sun S, Karna P, Lewis-Hunstiger M, Goldsmith JP. Breathsavers Group. Evaluation and development of potentially better practices to reduce bronchopulmonary dysplasia in very low birth weight infants. Pediatrics 2006; 118 Suppl 2:S65-S72.
10. Burch K, Rhine W, Baker R, Litman F, Kaempf JW, Schwarz E, Sun S, Payne NR, Sharek PJ. Implementing potentially better practices to reduce lung injury in neonates. Pediatrics 2003; 111(4 Pt 2):e432-e436.
11. Sharek PJ, Baker R, Litman F, Kaempf J, Burch K, Schwarz E, Sun S, Payne NR. Evaluation and development of potentially better practices to prevent chronic lung disease and reduce lung injury in neonates. Pediatrics 2003; 111(4 Pt 2):e426-e431.
12. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respi Crit Care Med 2001; 163:1723-1729.
13. MacDonald H. American Academy of Pediatrics. Committee on Fetus and Newborn. Perinatal Care at the Threshold of Viability. Pediatrics 2002; 110:1024-1027.
14. Ballard JL, Khoury JC, Wedig K, Wang L, Eilers-Walsman BL, Lipp R. New ballard score, expanded to include extremely premature infants. J Pediatr 1991; 119:417-423.
15. Rudolph AJ, Smith CA. Idiopathic respiratory distress syndrome of the newborn. J Pediatr 1960; 57:905-921.
16. Walsh MC, Kliegman RM. Necrotizing enterocolitis: treatment based on staging criteria. Ped Clin N Am 1986; 33:179-201.
17. An International classification of retinopathy of prematurity. Pediatrics 1984; 74:127-133.
18. The international classification of retinopathy of prematurity revisited. International Committee for the Classification of Retinopathy of Prematurity. Arch Ophthalmol 2005; 123:991-999.
19. Papile LA, Burstein J, Burstein R. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birthweights less than 1500g. J Pediatr 1978; 92:529-534.
20. de Vries L, Rennie JM. Preterm brain injury. In: Rennie JM, Roberton NRC. Textbook of neonatology, 3rd edition. Churchill Livingstone. London 1999: 1252-1270.
21. Bancalari E, Claure N, Sosenko IR. Bronchopulmonary dysplasia: changes in pathogenesis, epidemiology and definition. Semin Neonatol 2003; 8(1):63-71.
22. Walsh M, Engle W, Laptook A, Kazzi SN, Buchter S, Rasmussen M, Yao Q. National Institute of Child Health and Human Development Neonatal Research Network. Oxygen delivery through nasal cannulae to preterm infants: can practice be improved? Pediatrics 2005; 116(4):857-861.
23. Crowley P. Prophylactic corticosteroids for preterm birth. Cochrane Database Syst Rev 2007; 18(3):CD000065.
24. Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 2006; 19(3):CD004454
25. National Institutes of Health Consensus Development Panel. Antenatal corticosteroids revisited: repeat courses - National Institutes of Health Consensus Development Conference Statement, August 17-18, 2000. Obstet Gynecol 2001; 98(1):144-150.
26. Crowther CA, Harding JE. Repeat doses of prenatal corticosteroids for women at risk of preterm birth for preventing neonatal respiratory disease. Cochrane Database Syst Rev 2007; 18;(3):CD003935.
27. Collaborative European Multicenter Study Group. Surfactant replacement therapy for severe neonatal respiratory distress syndrome: an international randomized clinical trial. Pediatrics 1988; 82(5):683-691.
28. Chotigeat U, Promwong N, Kanjanapattanakul W, Khorana M, Sangtawesin V, Horpaopan S. Comparison outcomes of surfactant therapy in respiratory distress syndrome in two periods. J Med Assoc Thai 2008; 91 (Suppl 3):S109-S114.
29. Halliday HL, O'Neil CP. What is the evidence for drug therapy in the prevention and management of bronchopulmonary dysplasia? In: The newborn lung. Neonatal questions and controversies. Eduardo Bancalari. Ed Richard A Polin. Saunders Elsevier 2008:208-232.
30. Stevens TP, Harrington EW, Blennow M, Soll RF. Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. Cochrane Database Syst Rev 2007; 17(4):CD003063.
31. Soll R, Ozek E. Multiple versus single doses of exogenous surfactant for the prevention or treatment of neonatal respiratory distress syndrome. Cochrane Database Syst Rev 2009;21(1):CD000141.
32. Ramanathan RJ. Surfactant therapy in preterm infants with respiratory distress syndrome and in nearterm or term newborns with acute RDS. Perinatol 2006; 26(Suppl 1):S51-S56; discussion S63-S64.
33. VLBW infants in Portugal. National Multicenter Study 1996-2000. Portuguese Neonatal Network. Bial Award of Clinical Medicine 2002. ISBN 972-99224-0-3.
34. Ramanathan R. Choosing a right surfactant for respiratory distress syndrome treatment. Neonatology 2009; 95(1):1-5.
35. Oh W, Poindexter BB, Perritt R, Lemons JA, Bauer CR, Ehrenkranz RA, Stoll BJ, Poole K, Wright LL; Neonatal Research Network. Association between fluid intake and weight loss during the first ten days of life and risk of bronchopulmonary dysplasia in extremely low birth weight infants. J Pediatr 2005;147(6):786-790.
36. Stephens BE, Gargus RA, Walden RV, Mance M, Nye J, McKinley L, Tucker R, Vohr BR. Fluid regimens in the first week of life may increase risk of patent ductus arteriosus in extremely low birth weight infants. J Perinatol 2008; 28(2):123-128.
37. Bell EF, Acarregui MJ. Restricted versus liberal water intake for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2008; (1):CD000503.
38. Ramanathan R. Optimal ventilatory strategies and surfactant to protect the preterm lungs. Neonatology 2008; 93(4):302-308.
39. Bohlin K, Jonsson B, Gustafsson AS, Blennow M. Continuous positive airway pressure and surfactant. Neonatology 2008; 93(4):309-315.
40. Ramanathan R, Sardesai S. Lung protective ventilatory strategies in very low birth weight infants. J Perinatol 2008;28(Suppl 1):S41-S46.
41. Patel D, Greenough A. Does nasal CPAP reduce bronchopulmonary dysplasia (BPD)? Acta Paediatr 2008; 97(10):1314-1317.
42. Saugstad OD. Take a breath - but do not add oxygen (if not needed). Acta Paediatr 2007; 96(6):798-800.
43. Saugstad OD, Ramji S, Soll RF, Vento M. Resuscitation of newborn infants with 21% or 100% oxygen: an updated systematic review and meta-analysis. Neonatology 2008; 94(3):176-182.
44. Tin W, Gupta S. Optimum oxygen therapy in preterm babies. Arch Dis Child Fetal Neonatal. 2007; 92(2):F143-F147.
45. Sola A. Oxygen in neonatal anesthesia: friend or foe? Curr Opin Anaesthesiol 2008; 21(3):332-339.
46. STOP-ROP Multicenter Study Group. Supplemental therapeutic oxygen for pretreshold retinopathy of prematurity (STOP-ROP), a randomized controlled trial. I: Primary outcomes. Pediatrics 2000; 105:295-310.
47. Tin W, Wiswell TE. Adjunctive therapies in chronic lung disease: examining the evidence. Semin Fetal Neonatal Med 2008; 13(1):44-52.
48. Speer CP. Inflammation and bronchopulmonary dysplasia: a continuing story. Semin Fetal Neonatal Med 2006; 11(5):354-362.
49. Bose CL, Dammann CE, Laughon MM. Bronchopulmonary dysplasia and inflammatory biomarkers in the premature neonate. Arch Dis Child Fetal Neonatal 2008; 93(6):F455-F461.
50. Groneck P, Schmale J, Soditt V, Stützer H, Götze-Speer B, Speer CP. Bronchoalveolar inflammation following airway infection in preterm infants with chronic lung disease. Pediatr Pulmonol 2001; 31(5):331-338.
51. Rocha G, Proença E, Quintas C, Rodrigues T, Guimarães H. Chorioamnionitis and lung damage in the extremely low birth weight infant. Rev Port Pneumol 2007; 3(5):745-754.
52. Gonzalez A, Sosenko IR, Chandar J, Hummler H, Claure N, Bancalari E. Influence of infection on patent ductus arteriosus and chronic lung disease in premature infants weighing 1000 grams or less. J Pediatr 1996; 128(4):470-478.
53. Liljedahl M, Bodin L, Schollin J. Coagulase-negative staphylococcal sepsis as a predictor of bronchopulmonary dysplasia. Acta Paediatr 2004; 93(2):211-215.
54. Moro M, Pérez-Rodriguez J, Figueras-Aloy J, Fernández C, Doménech E, Jiménez R, Pérez-Sheriff V, Quero J, Roques V. Predischarge morbidities in extremely and very low-birth-weight infants in spanish neonatal units. Am J Perinatol 2008; 17.
55. Golombek SG, Sola A, Baquero H, Borbonet D, Cabañas F, Fajardo C, Goldsmit G, Lemus L, Miura E, Pellicer A, Pérez JM, Rogido M, Zambosco G, van Overmeire B; Primer Grupo de Consenso Clínico SIBEN (Golombek SG, Sola A, Clyman R, van Overmeire B, Goldsmit G, Natta D, Zambosco G, Miura E, Péerez JM, Weissheimer C, Baquero H, García Harker J, Oviedo Barrantes AN, Morgues M, Tapia JL, Domínguez F, Majano M, Cabañas F, Pellicer A, Cruz H, Fajardo C, Rogido M, Lemus L, Origel AV, Lacarruba JM, Lee M, Tresierra J, Guimarães H, Bustos R, Borbonet D, Perales JL. First SIBEN clinical consensus: diagnostic and therapeutic approach to patent ductus arteriosus in premature newborns. An Pediatr 2008; 69(5):454-481.
56. Ohlsson A, Walia R, Shah S. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2008; 23;(1):CD003481.
57. Mosalli R, Alfaleh K. Prophylactic surgical ligation of patent ductus arteriosus for prevention of mortality and morbidity in extremely low birth weight infants. Cochrane Database Syst Rev 2008; 23;(1):CD006181.
58. McCurnin D, Seidner S, Chang LY, Waleh N, Ikegami M, Petershack J, Yoder B, Giavedoni L, Albertine KH, Dahl MJ, Wang ZM, Clyman RI. Ibuprofen-induced patent ductus arteriosus closure: physiologic, histologic, and biochemical effects on the premature lung. Pediatrics 2008; 121(5):945-956.
59. Lundqvist P, Källén K, Hallström I, Westas LH. Trends in outcomes for very preterm infants in the southern region of Sweden over a 10-year period. Acta Paediatr 2009; 98(4):648-653.